<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228513</url>
  </required_header>
  <id_info>
    <org_study_id>15267</org_study_id>
    <secondary_id>1403380</secondary_id>
    <nct_id>NCT01228513</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)</brief_title>
  <official_title>Double-blind, Randomized, Vehicle-controlled, Multicenter, Multinational, Parallel-group Study of the Efficacy and Safety of ZK245186 Ointment in Concentrations of 0.01, 0.03, and 0.1% Over 4 Weeks in Patients With Atopic Dermatitis (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of three concentrations of a
      development drug compared to placebo in the treatment of atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eczema Area and Severity Index (EASI)</measure>
    <time_frame>At baseline</time_frame>
    <description>Eczema area and severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EASI</measure>
    <time_frame>Measured after one week of treatment</time_frame>
    <description>Ezcema area and severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EASI</measure>
    <time_frame>Measured at the end of 2 weeks of treatment</time_frame>
    <description>Eczema area and severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EASI</measure>
    <time_frame>Measured at the end of 3 weeks of treatment</time_frame>
    <description>Eczema area and severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EASI</measure>
    <time_frame>Measured at the end of 4 weeks of treatment</time_frame>
    <description>Eczema area and severity index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects' assessment of pruritus</measure>
    <time_frame>Measured at baseline</time_frame>
    <description>Subjective measurement on a point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of pruritus</measure>
    <time_frame>Measured after one week of treatment</time_frame>
    <description>Subjective measurement on a point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of pruritus</measure>
    <time_frame>Measured after two weeks of treatment</time_frame>
    <description>Subjective measurement on a point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of pruritus</measure>
    <time_frame>Measured after three weeks of treatment</time_frame>
    <description>Subjective measurement on a point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's assessment of pruritus</measure>
    <time_frame>Measured after four weeks of treatment</time_frame>
    <description>Subjective measurement on a point scale</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>0.01% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lowest concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.03% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Middle concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Highest concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle without active)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZK245186</intervention_name>
    <description>Daily topical application</description>
    <arm_group_label>0.01% ointment</arm_group_label>
    <arm_group_label>0.03% ointment</arm_group_label>
    <arm_group_label>0.1% ointment</arm_group_label>
    <other_name>Mapracorat (BAY86-5319)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (vehicle without active ingredient)</intervention_name>
    <description>Daily topical application</description>
    <arm_group_label>Placebo (vehicle without active)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria

          -  Body surface area affected by atopic dermatitis at or less than 15% at start of
             treatment

        Exclusion Criteria:

          -  Pregnancy and breast-feeding

          -  Conditions that may pose a threat to the patient or effect the outcome of the study

          -  Wide-spread atopic dermatitis (AD) requiring systemic treatment

          -  Immuno-compromized conditions

          -  At least 2 weeks after local AD treatment and treatment with systemic antibiotics

          -  At least 1 month after systemic AD treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawaguchi Saitama</city>
        <zip>332-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>150-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <disposition_first_submitted>June 4, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 4, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 1, 2015</disposition_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

